Literature DB >> 17082324

The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies.

Nathalie Satta1, Sylvie Dunoyer-Geindre, Guido Reber, Richard J Fish, Francoise Boehlen, Egbert K O Kruithof, Philippe de Moerloose.   

Abstract

Antiphospholipid antibodies (APLAs) promote inflammatory and procoagulant responses in endothelial cells and monocytes. Previous studies have shown that MyD88, TRAF6, and NF-kappaB mediate cell activation by APLAs. These intermediates are also used by toll-like receptors (TLRs). We investigated the role of TLRs in the cellular response to APLAs. IgGs were isolated from the plasma of 5 patients with antiphospholipid syndrome along with immunopurified anti-beta2-glycoprotein 1 IgG from a sixth patient. Control IgG was obtained from a pool of healthy donor plasmas negative for APLAs. Wild-type mouse embryonic fibroblasts (EFs) and EFs deficient in TLR1, TLR2, TLR4, or TLR6 were incubated with APLAs, anti-beta2-glycoprotein 1 IgG, or control IgG. On incubation with the patient IgG, but not control IgG, a significant increase in mRNA levels of the inflammatory marker proteins MCP-1, ICAM-1, and IL-6 as well as IL-6 secretion was observed in wild-type EFs, whereas TLR2-deficient EFs did not respond. Responses in TLR1- and TLR6-deficient EFs were decreased and those in TLR4-deficient EFs comparable to those in wild-type EFs. Overexpression of human TLR2 in the TLR2-deficient EFs restituted the response to patient IgG. Our results imply that TLR2 plays a role in mouse fibroblast activation by APLAs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082324     DOI: 10.1182/blood-2005-03-024463

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  Polymicrobial sepsis and endotoxemia promote microvascular thrombosis via distinct mechanisms.

Authors:  K N Patel; S H Soubra; F W Lam; M A Rodriguez; R E Rumbaut
Journal:  J Thromb Haemost       Date:  2010-03-12       Impact factor: 5.824

3.  Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome.

Authors:  Zurina Romay-Penabad; Renan Aguilar-Valenzuela; Rolf T Urbanus; Ronald H W M Derksen; Maarten T T Pennings; Elizabeth Papalardo; Tuya Shilagard; Gracie Vargas; Yong Hwang; Philip G de Groot; Silvia S Pierangeli
Journal:  Blood       Date:  2010-11-30       Impact factor: 22.113

Review 4.  Pathogenesis of antiphospholipid syndrome: understanding the antibodies.

Authors:  Pier Luigi Meroni; M Orietta Borghi; Elena Raschi; Francesco Tedesco
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

5.  TLR2 modulates antibodies required for intestinal ischemia/reperfusion-induced damage and inflammation.

Authors:  Michael R Pope; Sherry D Fleming
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

6.  Pathogenic anti-DNA antibodies modulate gene expression in mesangial cells: involvement of HMGB1 in anti-DNA antibody-induced renal injury.

Authors:  Xiaoping Qing; Milena Pitashny; David B Thomas; Franck J Barrat; Mark P Hogarth; Chaim Putterman
Journal:  Immunol Lett       Date:  2008-09-24       Impact factor: 3.685

7.  Pathophysiological mechanisms in antiphospholipid syndrome.

Authors:  Brock E Harper; Rohan Wills; Silvia S Pierangeli
Journal:  Int J Clin Rheumtol       Date:  2011-04-01

Review 8.  Autoantibodies to apolipoprotein A-1 as a biomarker of cardiovascular autoimmunity.

Authors:  Nicolas Vuilleumier; Fabrizio Montecucco; Oliver Hartley
Journal:  World J Cardiol       Date:  2014-05-26

9.  Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.

Authors:  Valerie Proulle; Richard A Furie; Glenn Merrill-Skoloff; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2014-05-13       Impact factor: 22.113

10.  Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways.

Authors:  Anastasia Lambrianides; Christopher J Carroll; Silvia S Pierangeli; Charis Pericleous; Ware Branch; Jurhee Rice; David S Latchman; Paul Townsend; David A Isenberg; Anisur Rahman; Ian P Giles
Journal:  J Immunol       Date:  2010-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.